Key result
Female sex in STEMI linked to ~58% lower thrombolytic use and higher mortality vs men.
Why the study?
Gender differences in pharmacotherapy and outcomes of STEMI in real clinical practice were not well characterized.
Does female sex affect pharmacotherapy prescription rates and mortality in patients with STEMI in real clinical practice?
Observational (n=153)
No
Does female sex affect pharmacotherapy prescription rates and mortality in patients with STEMI in real clinical practice?
Absolute Event Rate: 21% vs 50%
p-value: p=<0.05
Female STEMI patients receive less guideline-directed medical therapy and experience higher hospital and 12-month mortality compared to male patients, partly driven by older age and higher comorbidity rates.
Suggests possible undertreatment of women with STEMI; leaves open whether targeted strategies narrow mortality gaps.
Aim. To analyze gender differences in pharmacotherapy and outcomes of ST-elevation myocardial infarction (STEMI) in patients of cardiology hospital in real clinical practice. Material and methods. A continuous pharmacoepidemiological analysis was performed on the base of 153 records of patients with STEMI (men 102, women 51), consecutively admitted to the emergency department of cardiology hospital in the period from October 2010 to April 2011. Results. Women were on average 10.6 years older than men, had significantly higher incidence of severe comorbid conditions and significantly fewer prescribed medications improving STEMI prognosis - thrombolytics (21% vs 50%; p<0.05), statins (20% vs 53%; p<0.05), beta-blockers (84% vs 91%; p<0.05) and dual antiplatelet therapy (21% vs 59%; p<0.05). Hospital mortality was significantly higher in women than this in men, at that mortality differences persisted for 12 months after discharge. Conclusion. Older age, higher comorbidity rate, and lower treatment compliance with the current clinical recommendations in female STEMI patients in comparison with these in male STEMI patients contribute to higher hospital mortality and 12-month mortality after discharge in women with STEMI.
No takes yet. Share an insight, caveat, or question.
Dolotovskaya et al. (2013) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=153). Female gender vs. Male gender was evaluated on Prescription of thrombolytics (p=<0.05). Female STEMI patients received significantly fewer prognostic medications, such as thrombolytics (21% vs 50%, p<0.05), and experienced higher hospital and 12-month mortality compared to men.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: